Preclinical evaluation of zifaxaban, an oral inhibitor of factor Xa for thromboembolic diseases Nov. 28, 2018
Promacta granted FDA approval for first-line SAA and breakthrough therapy designation for H-ARS Nov. 19, 2018
RSS